Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) on November 24, 2020. The report details a corporate action involving the exchange of preferred stock for common stock.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on a capital structure transaction.
Material Changes
- Stock Exchange: The Company exchanged 4,205,406 shares of Series C Convertible Preferred Stock for 6,078,125 shares of common stock.
- Scope: This transaction represented all issued and outstanding shares of the Series C Preferred Stock.
- Method: The exchange was conducted without registration under the Securities Act of 1933, relying on the Section 3(a)(9) exemption for exchanges with existing security holders.
- Compensation: No commission or remuneration was paid for soliciting the exchange.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure of the unregistered sale of equity securities.
Investor Verification Checklist
- Verify the exact conversion ratio applied to the Series C Preferred Stock.
- Confirm the impact of the 6,078,125 new common shares on total outstanding share count and potential dilution.
- Review the Certificate of Designations for the Series C Preferred Stock to understand the original conversion terms.
- Check subsequent filings for any registration statements required to make the newly issued common stock freely tradable.